• Medicago Inc., of Quebec City, and the Infectious Disease Research Institute (IDRI) in Seattle reported interim results from a Phase I trial testing an H5N1 avian influenza virus-like particle vaccine candidate, showing that it was safe and well tolerated and induced a solid immune response exceeding the three Committee for Medicinal Products for Human Use immunogenicity criteria for licensure of influenza vaccines.